预处理淋巴细胞与单核细胞比值可预测泌尿系统癌症患者的临床结局：一项荟萃分析。

The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with urological cancers: A meta-analysis.

作者信息

Li Menglan, Deng Qianyun, Zhang Lei, He Siying, Rong Jialing, Zheng Fang

机构信息

Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei, China.

出版信息

Pathol Res Pract. 2019 Jan;215(1):5-11. doi: 10.1016/j.prp.2018.10.026. Epub 2018 Oct 24.

DOI:10.1016/j.prp.2018.10.026

PMID:30401580

Abstract

BACKGROUND

The lymphocyte to monocyte ratio (LMR), a novel systematic biomarker of inflammation, has been reported to be associated with the progression and prognosis of many malignant cancers. However, the relationship between LMR and survival outcome of urological cancers (UCs) remains controversial. Herein, we conducted a meta-analysis to identify the prognostic value of pretreatment LMR in patients with UCs.

METHODS

A literature search was performed in PubMed, Web of Science, Embase, Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, and CINAHL databases up to July 2018. The pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the association of LMR with survival outcome and clinicopathological characteristics in UCs.

RESULTS

A total of 17 articles containing 5552 patients were included in our study. The synthesized analysis showed that elevated pretreatment LMR level could predict favorable overall survival (OS) of UCs patients (pooled HR = 0.82, 95%CI: 0.77-0.87). Additionally, the decreased LMR level was correlated with tumor stage (OR = 1.72, 95%CI: 1.15-2.55), lymph node metastasis (OR = 1.46, 95%CI:1.06-1.99), grade (OR = 1.79, 95%CI:1.41-2.27), tumor size (OR = 2.21, 95%CI:1.81-2.68) and necrosis (OR = 1.71, 95%CI:1.36-2.16).

CONCLUSION

The high pretreatment LMR was associated with favorable prognosis, and could be a potential prognostic biomarker in patients with UCs.

摘要

背景

淋巴细胞与单核细胞比值（LMR）作为一种新型的炎症系统性生物标志物，已被报道与多种恶性肿瘤的进展及预后相关。然而，LMR与泌尿系统癌症（UCs）生存结局之间的关系仍存在争议。在此，我们进行了一项荟萃分析，以确定UCs患者治疗前LMR的预后价值。

方法

截至2018年7月，在PubMed、Web of Science、Embase、Cochrane图书馆、Cochrane对照试验中心注册库、Scopus和CINAHL数据库中进行文献检索。计算合并风险比（HRs）和比值比（ORs）以及相应的95%置信区间（CIs），以评估LMR与UCs生存结局及临床病理特征之间的关联。

结果

我们的研究共纳入17篇文章，包含5552例患者。综合分析表明，治疗前LMR水平升高可预测UCs患者良好的总生存期（OS）（合并HR = 0.82，95%CI：0.77 - 0.87）。此外，LMR水平降低与肿瘤分期（OR = 1.72，95%CI：1.15 - 2.55）、淋巴结转移（OR = 1.46，95%CI：1.06 - 1.99）、分级（OR = 1.79，95%CI：1.41 - 2.27）、肿瘤大小（OR = 2.21, 95%CI：1.81 - 2.68）和坏死（OR = 1.71，95%CI：1.36 - 2.16）相关。